Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal

Centessa Pharmaceuticals (NASDAQ:CNTA) is 1 of the best up and coming stocks to bargain according to Wall Street. On January 5, Needham raised the firm’s terms people connected Centessa to $38 from $35 with a Buy standing connected the shares. Needham suggested that Centessa’s banal momentum is poised to persist done 2026 owed to the forthcoming information from the dose-escalation cohorts of the ongoing ORX-750 Phase 2a study. Consequently, the steadfast identified the institution arsenic 1 of the astir compelling acquisition targets wrong the biotech assemblage for the coming year.

Furthermore, connected December 10, Oppenheimer assumed sum of Centessa with an Outperform standing with a terms people of $62, which was brought up from $40. The steadfast has been designated a apical prime by Oppenheimer, mostly owed to its pipeline of perchance best-in-class orexin agonists. Oppenheimer anticipates a commercialized motorboat successful H1 2028, projecting that these treatments volition dramatically broaden the narcolepsy marketplace by improving diagnosis rates, diligent uptake, compliance, and pricing powerfulness comparative to existing therapies. Believing that the institution is presently importantly undervalued, the steadfast expects important banal appreciation driven by aggregate objective information readouts scheduled passim 2026 and the pursuing years.

In Q3 2025, Centessa Pharmaceuticals confirmed that its pb candidate, ORX750, showed imaginable best-in-class efficacy for treating Narcolepsy Type 1 (NT1), Type 2 (NT2), and Idiopathic Hypersomnia. Phase 2a information showed that debased doses of the oral OX2R agonist achieved statistically significant, dose-dependent normalization of wakefulness. Centessa Pharmaceuticals (NASDAQ:CNTA) is present prepared for a large objective enlargement successful Q1 2026. During this period, the institution expects to motorboat the ORX750 registrational program, initiate diligent studies for the highly potent ORX142, and statesman first-in-human trials for ORX489, its astir potent agonist to date.

Centessa Pharmaceuticals (NASDAQ:CNTA) is simply a clinical-stage pharmaceutical institution that discovers, develops, and delivers medicines.

While we admit the imaginable of CNTA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.